Levetiracetam Injection
Product Images NDC 72485-106

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72485-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dailydose (Formula1 1)

An instructional formula diagram showing the calculation of total daily dose in mL/day for Levetiracetam injection. It states that total daily dose equals the daily dose in mg/kg/day multiplied by patient weight in kg, divided by the concentration of 100 mg/mL.*

FDA Label Image

Clcr (Formula2 2)

The image shows text describing the formula for calculating creatinine clearance (CLcr), including adjustments for age, weight, serum creatinine, and body surface area (BSA) with a specific factor for female patients. It includes mathematical expressions for these calculations.*

FDA Label Image

Structure (Levitiracetamstrc)

Chemical structure of Levetiracetam showing the molecular arrangement including a pyrrolidone ring and side chains with ethyl and amide groups.*

FDA Label Image

Fig 1 (Levitiracetamfigure1 1)

A bar graph depicting the percentage of patients responding to treatments, including placebo and two doses of Levetiracetam (1000 mg/day and 3000 mg/day). The y-axis represents the percentage of patients, with values reaching up to approximately 40%. Three bars show 7.4% for placebo, 37.1% for 1000 mg/day Levetiracetam, and 39.6% for 3000 mg/day Levetiracetam, with patient counts listed below each group.*

FDA Label Image

Fig 2 (Levitiracetamfigure2 1)

A bar chart depicting the percentage of patients in three groups: Placebo (111 patients) at 6.3%, Levetiracetam 1000 mg/day (106 patients) at 20.8%, and Levetiracetam 2000 mg/day (105 patients) at 35.2%. The chart compares treatment effects of Levetiracetam dosages against placebo.*

FDA Label Image

Fig 3 (Levitiracetamfigure3 1)

Bar graph comparing the percentage of patients in two groups: placebo (N=104) with 14.4% and levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis indicates the percentage of patients from 0% to 45%. The graph highlights a higher percentage in the levetiracetam treatment group.*

FDA Label Image

Fig 4 (Levitiracetamfigure4 1)

A bar chart comparing the percentage of patients between two groups: Placebo (97 patients) and Levetiracetam (101 patients). The Placebo group shows 19.6% of patients, while the Levetiracetam group shows 44.6%. The y-axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Fig 5 (Levitiracetamfigure5 1)

A bar chart comparing the percentage of patients between two groups: Placebo (N=51) with 19.6% and Levetiracetam (N=58) with 43.1%. The vertical axis represents the percentage of patients, ranging from 0% to 45%, and the horizontal axis shows the two groups assessed.*

FDA Label Image

Fig 6 (Levitiracetamfigure6 1)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The x-axis shows two groups: Placebo (N=84) and Levetiracetam (N=79). The y-axis is labeled '% of Patients' ranging from 0% to 100%. The Placebo group has 45.2% of patients, while the Levetiracetam group has 72.2%, indicated with an asterisk above the bar.*

FDA Label Image

Levetlbl3 (72485106 05)

Packaging labels for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) by Armas Pharmaceuticals Inc. The image shows inner vial and outer carton labels for single-dose vials of 5 mL. Labels indicate intravenous use, dilution requirement prior to administration, and storage instructions. Manufactured by Micro Labs Limited, India, and distributed by Armas Pharmaceuticals, Inc., Freehold, NJ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.